Research progress and value of albumin-related inflammatory markers in the prognosis of non-small cell lung cancer: a review of clinical evidence

Ann Med. 2023 Dec;55(1):1294-1307. doi: 10.1080/07853890.2023.2192047.

Abstract

Inflammatory markers have a wide range of predictive values in the prognosis of non-small lung cancer (NSCLC). Poor nutritional status usually means a poor prognosis in patients with NSCLC, which is widely recognized by oncologists and nutritionists. Serum albumin has a certain value in evaluating the prognosis of patients. Several inflammatory albumin-related markers have been proposed, but they have not been widely used in predicting the prognosis of NSCLC in clinical practice. We aim to systematically review the published clinical evidence of albumin-related inflammatory markers in predicting the prognosis of NSCLC and to describe their progress and value. The results showed that the markers included in the review could be prognostic indicators in patients with NSCLC. However, we found that the cut-off value of albumin-related inflammatory markers with quantitative nature was very chaotic and needed to be defined by recognized standards. We summarized and compared the advantages and disadvantages of these markers, but a prospective cohort study with long-term follow-up after adjustment for important confounders is still necessary. Whether the results and conclusions could be directly applied in clinical practice needs to be identified and evaluated. There is an urgent need to classify and standardize the albumin-related inflammatory markers that play an important role in the prognosis of NSCLC, which is the key to ensuring the transformation from clinical study to clinical application.

Keywords: Non-small lung cancer; albumin; inflammation; markers; prognosis.

Plain language summary

Albumin-related inflammatory markers could be prognostic indicators in non-small cell lung cancer.The classification and standardization of albumin-related inflammatory markers guarantee the transformation from clinical study to clinical application.Future prospective studies of albumin-related inflammatory markers excluding confounding factors are very necessary.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Carcinoma, Non-Small-Cell Lung* / diagnosis
  • Humans
  • Lung Neoplasms* / diagnosis
  • Prognosis
  • Prospective Studies
  • Retrospective Studies
  • Serum Albumin

Substances

  • Biomarkers
  • Serum Albumin

Grants and funding

The study was supported by a grant from Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences [grant number CI2021A01805], [grant number CI2021B009]; Science and Technology Commission Capital Clinical Diagnosis and Treatment Technology Research and Demonstration Application Project of Beijing [grant number Z191100006619022]; and Natural Science Foundation of Beijing [grant number 7222296].